<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Stem Cell Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Stem Cell Res Ther</journal-id><journal-title-group><journal-title>Stem Cell Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="epub">1757-6512</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28420441</article-id><article-id pub-id-type="pmc">5395856</article-id><article-id pub-id-type="publisher-id">541</article-id><article-id pub-id-type="doi">10.1186/s13287-017-0541-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Autologous bone marrow-derived cell transplantation in decompensated alcoholic liver disease: what is the impact on liver histology and gene expression patterns?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lanthier</surname><given-names>Nicolas</given-names></name><address><email>Nicolas.Lanthier@uclouvain.be</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin-Marq</surname><given-names>Nathalie</given-names></name><address><email>Nathalie.Linmarq@hcuge.ch</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Rubbia-Brandt</surname><given-names>Laura</given-names></name><address><email>Laura.Rubbia-Brandt@hcuge.ch</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Cl&#x000e9;ment</surname><given-names>Sophie</given-names></name><address><email>Sophie.Clement@unige.ch</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Goossens</surname><given-names>Nicolas</given-names></name><address><email>Nicolas.Goossens@hcuge.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Spahr</surname><given-names>Laurent</given-names></name><address><email>Laurent.Spahr@hcuge.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Gastroenterology and Hepatology, University Hospitals and Faculty of Medicine, 4, Rue Gabrielle Perret-Gentil CH-1211, Geneva 14, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 2294 713X</institution-id><institution-id institution-id-type="GRID">grid.7942.8</institution-id><institution>Laboratory of Gastroenterology and Hepatology, Institut de Recherche Exp&#x000e9;rimentale et Clinique, </institution><institution>Universit&#x000e9; catholique de Louvain, </institution></institution-wrap>Brussels, Belgium </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0721 9812</institution-id><institution-id institution-id-type="GRID">grid.150338.c</institution-id><institution>Clinical Pathology, </institution><institution>University Hospitals and Faculty of Medicine, </institution></institution-wrap>Geneva, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>4</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>8</volume><elocation-id>88</elocation-id><history><date date-type="received"><day>22</day><month>12</month><year>2016</year></date><date date-type="rev-recd"><day>20</day><month>3</month><year>2017</year></date><date date-type="accepted"><day>22</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2017</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Liver stem cell therapy (SCT) has been suggested as a promising means to improve liver regeneration in advanced liver disease. However, data from trials are heterogeneous, with no systematic histological evaluation. The aim of this study is to specifically analyze the effect of autologous SCT on liver regeneration and on gene expression changes.</p></sec><sec><title>Methods</title><p>Individuals in the randomized controlled trial of SCT in alcoholic hepatitis with paired liver biopsies were included (<italic>n</italic>&#x02009;=&#x02009;58). Immunohistochemistry (Ki67, K7, and CD68), in situ hybridization (SPINK1), and global gene expression analysis were performed on liver biopsies (30 control patients and 28 patients with transarterial administration of bone marrow-derived stem cells) both at baseline and after 4&#x000a0;weeks of follow-up.</p></sec><sec><title>Results</title><p>No difference between the two groups could be observed regarding the proliferative hepatocyte number, proliferative K7-positive cells, or total K7-positive cells at the 4-week follow-up liver biopsy. However, patients who received SCT showed a more important liver macrophagic expansion as compared to standard treatment. Transcriptome data revealed changes in genes linked with inflammation (CD68 and SAA), regeneration (SPINK1 and HGF), fibrosis (COL1A1), and stem cells (CD45). No changes in gene pathways involved in liver growth and cell cycle proteins were evident. SPINK1 mRNA was present by in situ hybridization at week 4 in SCT patients in the liver parenchyma areas adjacent to macrophage recruitment and liver cell proliferation.</p></sec><sec><title>Conclusions</title><p>The analysis of liver tissue after SCT demonstrated an expansion of macrophages concurrent with an upregulated expression of genes involved in inflammatory and regenerative pathways. With the negative results from the clinical trial, the impact of the SCT has to be interpreted as weak, and it is not able to modify the clinical course of this severe liver disease.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13287-017-0541-2) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Stem cell transplantation</kwd><kwd>Macrophage</kwd><kwd>Kupffer cell</kwd><kwd>SPINK1</kwd><kwd>CD68</kwd><kwd>HGF</kwd><kwd>Alcoholic hepatitis</kwd><kwd>Cirrhosis</kwd></kwd-group><funding-group><award-group><funding-source><institution>Clinical Research Center, H&#x000f4;pitaux Universitaires de Gen&#x000e8;ve</institution></funding-source></award-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001706</institution-id><institution>Louis-Jeantet Foundation</institution></institution-wrap></funding-source></award-group><award-group><funding-source><institution>FLAGS (Foundation for Liver and Gut Studies)</institution></funding-source></award-group><award-group><funding-source><institution>Fondation Saint-Luc</institution></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>There is a great interest in stem cell therapy (SCT) in the setting of an increased burden of chronic decompensated liver diseases and an organ shortage for liver transplantation. Accordingly, decompensated alcoholic liver disease (ALD) with alcoholic hepatitis (AH) carries a poor prognosis with elevated short-term mortality even in steroid-treated patients. Early liver transplantation can be an option in very select patients, but this treatment strategy is unavailable to the majority of patients [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Stem cell-based strategies have been tested as an alternative to organ transplantation. However, limitations of clinical trials that aimed to explore the effect of granulocyte-colony stimulating factors (GCSF) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and/or stem cell transplantation [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] include lack of power due to the small sample size and major heterogeneity in the protocol design (including absence of systematic liver biopsy), disease etiologies, endpoints, methods of stem cell collection (from the bone marrow or from the blood, with or without cell mobilization by GCSF), cell infusion number, and route of administration. The results of those investigations are summarized in two recent reviews [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. In particular, systematic investigations of SCT in AH (controlled and histologically based) are of great importance with regards to the heterogeneity of the disease, the role of alcohol abstinence, and the possible impact on specific pathways.</p><p>In a recent randomized controlled trial [<xref ref-type="bibr" rid="CR8">8</xref>], identified as a high-quality study [<xref ref-type="bibr" rid="CR6">6</xref>], we investigated the effect of autologous bone marrow stem cell transplantation (SCT) in AH and explored the evolution of histological alterations during follow-up using a repeat liver biopsy at 4&#x000a0;weeks. Although our trial did not demonstrate any clinical benefit in terms of the model for end-stage liver disease (MELD) score changes over a 3-month period, nor any differences in progenitor cell proliferation by immunohistochemistry on repeat liver biopsy [<xref ref-type="bibr" rid="CR8">8</xref>], we felt that further investigations were needed on liver histology and on hepatic gene expression. In particular, the impact of SCT on proliferating hepatocytes, total K7 progenitor cells, and also hepatic macrophages remained to be analyzed. Indeed, macrophages constitute a heterogeneous population within the liver, both promoting detrimental inflammation and also being involved in regenerative response after injury, and have been identified as good prognosis markers [<xref ref-type="bibr" rid="CR9">9</xref>&#x02013;<xref ref-type="bibr" rid="CR11">11</xref>]. Actually, previous results highlighted that improvers (patients with a significant improvement of liver function defined by a decrease in MELD score of 3 points or more at 3&#x000a0;months) were characterized at baseline by a significantly higher number of proliferating hepatocytes, proliferative K7 progenitor cells, and higher macrophage infiltration compared to nonimprovers (defined as patients with MELD deterioration or MELD improvement lower than 3 points at 3&#x000a0;months or patients who died during this 3-month follow-up).</p><p>Thus, the aim of this study was to perform an in-depth histological and transcriptome analysis both at baseline and at repeat liver biopsy performed after 4&#x000a0;weeks in order to detect whether SCT was associated with specific changes in macrophages and regenerative pathways.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Patients and tissue collection</title><p>Data for this study were obtained from participants in the autologous SCT in decompensated alcoholic liver disease trial [<xref ref-type="bibr" rid="CR8">8</xref>]. Written informed consent was obtained in all cases and the study was accepted by our institution&#x02019;s ethics committee. According to recent guidelines [<xref ref-type="bibr" rid="CR12">12</xref>], the syndrome of AH was defined by a recent clinical decompensation (ascites and/or jaundice) in active drinkers (&#x02265;80&#x000a0;g/day until admission) and exclusion of other causes of decompensation such as ongoing infection, hepatocellular carcinoma, biliary tract obstruction, gastrointestinal bleeding, and portal vein thrombosis. Liver biopsy was performed by the transjugular route in all patients early after hospital admission and prior to specific therapeutic interventions. In all patients, liver histology showed established cirrhosis with superimposed acute lesions including steatosis. Histological lesions were evaluated by a blinded pathologist on hematoxylin and eosin stained histological slides using a semiquantitative scoring of steatosis, portal and lobular inflammation, and hepatocyte ballooning. After screening for those clinical and histological criteria, 58 patients with AH were included and divided into two groups: one (control) group received only standard of care management and another group received a single session of autologous SCT (CD34<sup>+</sup> stem cells and mesenchymal stem cells collected the same day from the bone marrow) into the hepatic artery following mobilization using a 5-day course of subcutaneous GCSF in addition to standard of care therapy (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Cell isolation and characterization procedures are described in our first report [<xref ref-type="bibr" rid="CR8">8</xref>]. The mean number of bone marrow-derived cells infused into the hepatic artery was 0.47&#x02009;&#x000b1;&#x02009;0.15&#x02009;&#x000d7;&#x02009;10<sup>8</sup>/kg, within the range seen in other studies [<xref ref-type="bibr" rid="CR13">13</xref>]. Standard of care management included vitamin B supplementation, renutrition, alcohol withdrawal, and treatment with prednisone 40&#x000a0;mg/day for 4&#x000a0;weeks when indicated (Maddrey discriminant function &#x02265;32 and histologically proven alcoholic steatohepatitis). A repeat liver biopsy was performed at 4&#x000a0;weeks, and follow-up information was carefully collected over 3&#x000a0;months. As for the first biopsy, the liver tissue was separated into two pieces, one for histological analysis and the other snap-frozen in liquid nitrogen and stored at &#x02013;80&#x000a0;&#x000b0;C for further gene expression analysis. Six patients died during the study (four in the control group and two in the SCT group). Improvement of liver function during follow-up as assessed by the MELD score was similar in the two groups and no differences could be observed in histological lesions between the two groups using hematoxylin and eosin staining.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient baseline inclusion characteristics according to treatment allocation</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Control patients (<italic>n</italic>&#x02009;=&#x02009;30)</th><th>SCT patients (<italic>n</italic>&#x02009;=&#x02009;28)</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td>Age (years)</td><td>57 (37&#x02013;69)</td><td>54 (35&#x02013;67)</td><td char="." align="char">0.15</td></tr><tr><td>Gender (M/F)</td><td>19/11</td><td>14/14</td><td char="." align="char">0.31</td></tr><tr><td>HVPG (mmHg)</td><td>19.9&#x02009;&#x000b1;&#x02009;2.4</td><td>19.1&#x02009;&#x000b1;&#x02009;2.8</td><td char="." align="char">0.28</td></tr><tr><td>MELD score</td><td>19.1&#x02009;&#x000b1;&#x02009;4.0</td><td>19.0&#x02009;&#x000b1;&#x02009;3.8</td><td char="." align="char">0.86</td></tr><tr><td>Cirrhosis (%)</td><td>100</td><td>100</td><td char="." align="char">0.99</td></tr><tr><td>ASH (n, %)</td><td>25 (83.3%)</td><td>22 (78.6%)</td><td char="." align="char">0.64</td></tr><tr><td>Corticosteroid treatment (n, %)</td><td>22 (73.3%)</td><td>16 (57.1%)</td><td char="." align="char">0.59</td></tr></tbody></table><table-wrap-foot><p>
<italic>ASH</italic> alcoholic steatohepatitis (full histological definition), <italic>F</italic> female, <italic>HVPG</italic> hepatic venous pressure gradient, <italic>M</italic> male, <italic>MELD</italic> model for end stage liver disease, <italic>SCT</italic> stem cell therapy</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec4"><title>Immunohistochemistry</title><p>All liver biopsy specimens (<italic>n</italic>&#x02009;=&#x02009;58 at baseline, <italic>n</italic>&#x02009;=&#x02009;52 at 4&#x000a0;weeks) were processed as previously described [<xref ref-type="bibr" rid="CR10">10</xref>]. Briefly, after fixation into formalin 10% and paraffin embedding, immunostainings were performed using the automated Ventana Discovery XT system (Ventana Medical Systems, Tucson, AZ, USA) and Ventana reagents. The mouse monoclonal human antibody MIB1 against the proliferation marker Ki67 (Dako, M7240, 1:100 dilution), anti-Keratin7 (K7; Dako, M7018, 1:100 dilution), and anti-CD68 (Dako, M0876, 1:100 dilution) were used as primary antibodies and detected.</p><p>Proliferation was assessed on the whole biopsy specimen by manual counting under very high magnification (&#x000d7;400). Results are given as the mean number of Ki67-positive cells per high-power field. Ki67-positive cells were classified either as K7-negative or -positive to assess either hepatocyte (Hep) or liver progenitor cell (LPC) proliferation. K7-positive cells were further classified by their histological appearance, localization in the liver lobule, and staining intensity of K7. Cells from the ductular reaction (DR) are cuboid adjacent K7 intense positive cells forming ductules. Intermediate progenitor cells (iPC) are K7-positive cells (often isolated) located in the liver lobule and are smaller than hepatocytes. Intermediate hepatocytes (IH) are large, cuboid hepatocyte-like cells with a less intense K7 staining. Total K7 and CD68 (a marker for liver macrophages) positive cell areas were quantified using tissue section photographs at high magnification (&#x000d7;100) of the entire liver biopsy and using the Leica QWin computer assisted program [<xref ref-type="bibr" rid="CR14">14</xref>]. Results are given as the percentage of total positive cell area (K7 or CD68) on the total biopsy surface at&#x02009;&#x000d7;&#x02009;100 magnification. As for hematoxylin and eosin staining evaluation, immunohistochemistry was analyzed in a blinded manner.</p></sec><sec id="Sec5"><title>In situ hybridization</title><p>The PCR template coding partially for human serine peptidase inhibitor Kazal type 1 (SPINK1) was generated from human pancreas RNA (AM7954, AMBION) using the reverse transcription kit from Takara (RR037A), and SPINK1 in situ hybridization with sense or antisense probes specific for human SPINK1 was performed on serial sections from paraffin-embedded human liver, as previously described [<xref ref-type="bibr" rid="CR10">10</xref>], with human pancreas tissue sections serving as positive controls.</p></sec><sec id="Sec6"><title>Transcription analysis</title><p>Transcriptome profiling was performed with Affymetrix arrays containing 49,395 transcripts. Total RNA was extracted from snap-frozen liver biopsies obtained at baseline (<italic>n</italic>&#x02009;=&#x02009;30) and after 4&#x000a0;weeks (<italic>n</italic>&#x02009;=&#x02009;24) using the TissueLyser machine (Qiagen) and the AllPrepDNA/RNA Mini Kit (Qiagen, Hombrechtikon, Switzerland). RNA quality was assessed by capillary electrophoresis on the Agilent 2100 Bioanalyzer (Agilent Technologies, Basel, Switzerland); 100&#x000a0;ng was amplified and labeled using the 3&#x02019; IVT Express kit (Affymetrix). Hybridization on GeneChip PrimeView Human Gene Expression arrays (Affymetrix) was carried out according to the manufacturer&#x02019;s instructions.</p><p>The data were robust multi-array normalized [<xref ref-type="bibr" rid="CR15">15</xref>]. Pathway analysis of the genes, which were identified as differentially expressed by the microarray experiment, was undertaken using the MetaCore software (<ext-link ext-link-type="uri" xlink:href="http://www.genego.com">http://www.genego.com</ext-link>). The gene expression data can be found in ArrayExpress (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/arrayexpress/">https://www.ebi.ac.uk/arrayexpress/</ext-link>) accession no. E-MTAB-2664.</p></sec><sec id="Sec7"><title>Nanostring</title><p>For the confirmation of the Affymetrix transcriptional analysis, 27 samples were assessed using the nCounter system (NanoString). NanoString synthesized the codeset for the analysis of 115 genes of interest and 7 normalization genes. RNA hybridization, sample processing, and calculation methods were performed as previously described [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec><sec id="Sec8"><title>Statistical analysis</title><p>Continuous variables are presented as means&#x02009;&#x000b1;&#x02009;SD and were compared using Student&#x02019;s <italic>t</italic> test (two-tails) or paired if appropriate. Categorical variables were compared using the chi square test. To assess the differences in gene expression values (Affymetrix and Nanostring) between the different groups (controls versus SCT at 4&#x000a0;weeks of follow-up, follow-up versus baseline in each group), we performed a 5-way analysis of variance (ANOVA) with contrast in Partek Genomics Suite (<ext-link ext-link-type="uri" xlink:href="http://www.partek.com">http://www.partek.com</ext-link>). We applied a significance threshold <italic>p</italic> value of 0.05.</p></sec></sec><sec id="Sec9"><title>Results</title><sec id="Sec10"><title>Effect of SCT on liver histology</title><p>At baseline, the control group and SCT group were comparable in terms of histological lesions (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Baseline and 4-week liver biopsies were evaluated with a paired comparison. As reported in our initial paper, patients who received SCT had a similar improvement of liver function over time as the controls, and did not exhibit any increased proliferative activity in K7-positive liver progenitor cells [<xref ref-type="bibr" rid="CR8">8</xref>]. This proliferating activity, counted on all liver slides with double K7 and Ki67 double immunohistochemistry, even decreased significantly between the baseline biopsy at week 0 and the second biopsy at week 4 (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> and <xref rid="Fig1" ref-type="fig">b</xref>). Hepatocyte (Hep) proliferation also decreased between week 0 and week 4, although not significantly, and was similar between SCT patients and controls (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> and <xref rid="Fig1" ref-type="fig">b</xref>). No significant change in total K7-positive cell area could be seen between week 0 and week 4 and following SCT (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1c</xref>). Double K7-Ki67-positive cells were evaluated in all K7 cell subtypes in the control and SCT patients at week 0 and week 4. The decrease in K7-Ki67-positive cells was significant for proliferative K7<sup>+</sup> intermediate progenitor cells (iPC), but not for other cell subtypes including cells from the ductular reaction (DR) and intermediate hepatocytes (IH) (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). Furthermore, there was no difference between SCT patients and controls (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1d</xref>). As reported previously [<xref ref-type="bibr" rid="CR8">8</xref>] and seen on histological sections, steatosis was present at baseline and dramatically decreased after 4&#x000a0;weeks of management (Figs.&#x000a0;<xref rid="Fig1" ref-type="fig">1a</xref> and <xref rid="Fig2" ref-type="fig">2a</xref>, and Additional file <xref rid="MOESM2" ref-type="media">2</xref>). This observation is in line with a sustained abstinence from alcohol in the majority of our patients.<fig id="Fig1"><label>Fig. 1</label><caption><p>Liver progenitor cell compartment analysis at baseline and 4&#x000a0;weeks in controls (<italic>CTL</italic>) and stem cell treated (<italic>SCT</italic>) patients. Total liver progenitor cells were identified by keratin 7 (<italic>K7</italic>) staining (<italic>pink</italic>) and proliferative cells were quantified by Ki67 staining (<italic>brown</italic>) (<bold>a</bold>). Double K7/Ki67-positive cells were manually counted (<bold>b</bold>) with the distinction of cells from the ductular reaction (<italic>DR</italic>), intermediate progenitor cells (<italic>iPC</italic>), or intermediate hepatocyte-like cells (<italic>IH</italic>) and K7-negative Ki67-positive cells with a hepatocyte morphology classified as proliferative hepatocytes (<italic>Hep</italic>) (<bold>d</bold>). Morphometric quantification of the area occupied by K7-positive cells is also presented (<bold>c</bold>). All data are shown as mean&#x02009;&#x000b1;&#x02009;SD. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 between groups</p></caption><graphic xlink:href="13287_2017_541_Fig1_HTML" id="MO1"/></fig>
<fig id="Fig2"><label>Fig. 2</label><caption><p>Macrophage compartment analysis at baseline and 4&#x000a0;weeks in controls (<italic>CTL</italic>) and stem cell treated (<italic>SCT</italic>) patients. Macrophages were stained with antibody against CD68 (<italic>brown</italic>) (<bold>a</bold>) allowing the morphometric quantification of the area occupied by those cells (<bold>b</bold>). Data are shown as mean&#x02009;&#x000b1;&#x02009;SD. *<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 between groups</p></caption><graphic xlink:href="13287_2017_541_Fig2_HTML" id="MO2"/></fig>
</p><p>Increased macrophage infiltration was identified in our baseline study analysis as a positive prognostic factor. Indeed, improvers show a significantly more important expansion of CD68-positive cells compared to nonimprovers at inclusion [<xref ref-type="bibr" rid="CR10">10</xref>]. We therefore completed our histological study by exploring whether the liver macrophagic compartment was affected by the stem cell therapy procedure. Both groups (controls and SCT) were comparable at baseline in terms of CD68 cell quantification (Additional file <xref rid="MOESM1" ref-type="media">1</xref>). In patients treated with SCT, but not in the control group, we observed a significant increase in the CD68-positive cell compartment at week 4 compared to baseline (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref> and <xref rid="Fig2" ref-type="fig">b</xref>). Macrophage content was also higher at 4&#x000a0;weeks in the SCT group compared to the control group, although it did not reach statistical significance (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2a</xref> and <xref rid="Fig2" ref-type="fig">b</xref>).</p><p>Finally, we explored SPINK1 mRNA expression on liver sections, this also being identified to be at higher levels in improvers in the baseline study [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. SPINK1 mRNA by in situ hybridization was present at week 4 in SCT patients in the liver parenchyma adjacent to macrophage recruitment and liver cell proliferation areas (Additional file <xref rid="MOESM2" ref-type="media">2</xref>).</p></sec><sec id="Sec11"><title>Effect of SCT on liver gene expression</title><p>Further analyses of gene expression patterns were performed in order to determine whether changes in the macrophage compartment were associated or not with any modification in inflammatory and/or regenerative pathways.</p><p>SCT was associated with significant changes (defined as fold-change over 2 and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) in only four transcripts when compared with standard therapy controls at week 4. SPINK1 and the C-X-C motif chemokine ligand (CXCL)6 were upregulated in SCT patients compared to controls, while CXCL14 and glutamate transporter GLT-1 (SLC1A2) were significantly downregulated (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Different expression of genes at the 4-week follow-up in stem cell treated patients compared to control patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Accession number</th><th>Gene name</th><th>Affymetrix fold-expression</th><th>
<italic>p</italic> value</th><th>Nanostring fold-expression</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="6">Macrophages, inflammation, and chemotaxis</td></tr><tr><td>&#x02003;NM_001040059, NM_001251</td><td>CD68<break/>CD68 molecule</td><td>1.11</td><td>0.5874</td><td>
<bold>5.19</bold>
</td><td>
<bold>0.0011</bold>
</td></tr><tr><td>&#x02003;NM_002993</td><td>CXCL6 (chemokine (C-X-C motif) ligand 6)</td><td>
<bold>2.03</bold>
</td><td>
<bold>0.0327</bold>
</td><td>3.42</td><td>0.2015</td></tr><tr><td>&#x02003;NM_002985</td><td>CCL5 (chemokine (C-C motif) ligand 5)</td><td>
<bold>1.53</bold>
</td><td>
<bold>0.0411</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_033439</td><td>IL33 (interleukin 33)</td><td>
<bold>1.53</bold>
</td><td>
<bold>0.0336</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_000331, NM_001127380, NM_001178006, NM_030754, NM_199161</td><td>SAA-1 (serum amyloid A1)</td><td>1.73</td><td>0.0692</td><td>
<bold>2.68</bold>
</td><td>
<bold>0.0455</bold>
</td></tr><tr><td>&#x02003;NM_001127380, NM_030754</td><td>SAA-2 (serum amyloid A2)</td><td>1.12</td><td>0.7873</td><td>
<bold>3.11</bold>
</td><td>
<bold>0.0202</bold>
</td></tr><tr><td>&#x02003;NM_004887</td><td>CXCL14 (chemokine (C-X-C motif) ligand 14)</td><td>
<bold>&#x02013;2.13</bold>
</td><td>
<bold>0.0458</bold>
</td><td>&#x02013;6.32</td><td>0.1257</td></tr><tr><td colspan="6">Liver regeneration and stem cells</td></tr><tr><td>&#x02003;NM_000601, NM_001010931, NM_001010932, NM_001010933, NM_001010934</td><td>HGF (hepatocyte growth factor)</td><td>1.11</td><td>0.4825</td><td>
<bold>7.50</bold>
</td><td>
<bold>0.0019</bold>
</td></tr><tr><td>&#x02003;NM_016639</td><td>TNFRSF12A (tumor necrosis factor receptor superfamily, member 12A)</td><td>1.15</td><td>0.4973</td><td>1.08</td><td>0.9551</td></tr><tr><td>&#x02003;NM_003122</td><td>SPINK1 (serine peptidase inhibitor, Kazal type 1)</td><td>
<bold>4.29</bold>
</td><td>
<bold>0.0446</bold>
</td><td>19.95</td><td>0.0979</td></tr><tr><td>&#x02003;NM_005556</td><td>CK7(keratin 7)</td><td>&#x02013;1.11</td><td>0.7284</td><td>&#x02013;3.38</td><td>0.3841</td></tr><tr><td>&#x02003;NM_002276</td><td>CK19(keratin 19)</td><td>1.04</td><td>0.8957</td><td>&#x02013;2.15</td><td>0.5533</td></tr><tr><td>&#x02003;NM_002838, NM_080921, NM_080923</td><td>PTPRC (CD45) (protein tyrosine phosphatase, receptor type, C)</td><td>
<bold>1.52</bold>
</td><td>
<bold>0.0473</bold>
</td><td>
<bold>8.98</bold>
</td><td>
<bold>0.0260</bold>
</td></tr><tr><td colspan="6">Fibrosis</td></tr><tr><td>&#x02003;NM_000088</td><td>COL1A1<break/>(collagen, type I, alpha 1)</td><td>1.38</td><td>0.1405</td><td>
<bold>10.54</bold>
</td><td>
<bold>0.0101</bold>
</td></tr><tr><td colspan="6">Other</td></tr><tr><td>&#x02003;NM_001142466, NM_133443</td><td>GPT2</td><td>
<bold>&#x02013;1.54</bold>
</td><td>
<bold>0.0201</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_001190463, NM_001902, NM_153742</td><td>&#x02013;</td><td>
<bold>&#x02013;1.83</bold>
</td><td>
<bold>0.0365</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_001195728, NM_004171</td><td>SLC1A2 (solute carrier family 1 (glial high affinity glutamate transporter), member 2)</td><td>
<bold>&#x02013;2.22</bold>
</td><td>
<bold>0.0147</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr></tbody></table><table-wrap-foot><p>Values shown in bold are significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p><p>Other significant (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) changes, but at a lower level (fold-change ranging from 1 to 2), could be observed for CD45, expressed in granulocytes and hematopoietic stem cells, inflammatory chemokine (C-C motif) ligand 5, and interleukin 33, glutamic pyruvate transaminase 2 (GPT2), and cystathionine gamma-lyase (CTH) involved in <sc>l</sc>-alanine, <sc>l</sc>-cysteine, and <sc>l</sc>-methionine metabolism (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). In this context, the three main pathways highlighted by the functional analysis of these transcriptome data using the MetaCore software were cell chemotaxis, the alpha-amino acid metabolic process, and regulation of the antigen receptor-mediating signaling pathway (Additional file <xref rid="MOESM3" ref-type="media">3</xref>). This analysis did not reveal any other important pathway and, in particular, no upstream or downstream regulators of SPINK1.</p><p>Genes related to the cell cycle, Wnt, or tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) signaling or liver function were unchanged, consistent with the absence of clinical and biological effects of SCT in patients with AH (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> or data not shown).</p><p>Nanostring analysis was then performed on selected genes in order to confirm these results. Interestingly, CD68 expression was significantly upregulated (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), in line with the histological data (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). In accordance with this upregulation of inflammation, serum amyloid A1 (SAA-1) was upregulated (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) as was SPINK1 expression, although the increase did not reach statistical significance.</p><p>Nanostring analysis also revealed a significant upregulation of hepatocyte growth factor (HGF) and also of collagen type 1 alpha1 (COL1A1) in SCT patients compared to controls at the 4-week liver biopsy. However, careful examination of the genes evolving between baseline and week 4 showed a significant downregulation of COL1A1 in both groups, although this was more pronounced in controls (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In accordance with the significant decrease in proliferative K7<sup>+</sup> cells, tumor necrosis factor receptor superfamily member 12A (TNFRSF12A), the receptor for TWEAK (involved in LPC proliferation), was significantly downregulated in controls and SCT patients (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). Other genes related to liver function or metabolism were also significantly modified between baseline and week 4 both in controls and SCT patients, such as detoxification enzyme glutathione S-transferase alpha 1 (GSTA1), cytochrome P450 family 7/1 subfamily A polypetides 1/2 (CYP7A1 and CYP1A2), lipoprotein A (LPA), aldo-ketoreductase family 1, member B10 (AKRB10), fatty acid binding protein 5 (FABP5), and superoxide dismutase 2 (SOD2) (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Different expression of genes at the 4-week follow-up in control patients and in stem cell treated patients compared to baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Accession number</th><th rowspan="2">Gene name</th><th colspan="4">Control patients</th><th colspan="4">SCT patients</th></tr><tr><th>Affymetrix fold-expression</th><th>
<italic>p</italic> value</th><th>Nanostring fold-expression</th><th>
<italic>p</italic> value</th><th>Affymetrix fold-expression</th><th>
<italic>p</italic> value</th><th>Nanostring fold-expression</th><th>
<italic>p</italic> value</th></tr></thead><tbody><tr><td colspan="10">Macrophages, inflammation and chemotaxis</td></tr><tr><td>&#x02003;NM_001040059, NM_001251</td><td>CD68<break/>CD68 molecule</td><td>&#x02013;1.16</td><td>0.0740</td><td>&#x02013;1.65</td><td>0.3234</td><td>&#x02013;1.13</td><td>0.1404</td><td>1.00</td><td>0.9935</td></tr><tr><td>&#x02003;NM_001130046, NM_004591</td><td>CCL20 (chemokine (C-C motif) ligand 20)</td><td>
<bold>&#x02013;1.78</bold>
</td><td>
<bold>0.0234</bold>
</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>&#x02013;2.26</bold>
</td><td>
<bold>0.0032</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_003955</td><td>SOCS3 (suppressor of cytokine signaling 3)</td><td>&#x02013;1.30</td><td>0.1987</td><td>&#x02013;6.5</td><td>0.0574</td><td>
<bold>&#x02013;1.96</bold>
</td><td>
<bold>0.0033</bold>
</td><td>
<bold>&#x02013;28.96</bold>
</td><td>
<bold>0.0017</bold>
</td></tr><tr><td>&#x02003;NM_002228</td><td>JUN (jun proto-oncogene)</td><td>
<bold>&#x02013;1.65</bold>
</td><td>
<bold>0.0212</bold>
</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>&#x02013;2.07</bold>
</td><td>
<bold>0.0021</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_004887</td><td>CXCL14 (chemokine (C-X-C motif) ligand 14)</td><td>&#x02013;1.07</td><td>0.7539</td><td>&#x02013;1.39</td><td>0.6367</td><td>
<bold>&#x02013;1.70</bold>
</td><td>
<bold>0.0278</bold>
</td><td>
<bold>&#x02013;8.48</bold>
</td><td>
<bold>0.0057</bold>
</td></tr><tr><td>&#x02003;NM_001100812, NM_022059</td><td>CXCL16 (chemokine (C-X-C motif) ligand 16)</td><td>
<bold>&#x02013;1.18</bold>
</td><td>
<bold>0.0351</bold>
</td><td>&#x02013;<bold>6.37</bold>
</td><td>
<bold>0.0355</bold>
</td><td>
<bold>&#x02013;1.19</bold>
</td><td>
<bold>0.0342</bold>
</td><td>
<bold>&#x02013;16.20</bold>
</td><td>
<bold>0.0029</bold>
</td></tr><tr><td colspan="10">Liver regeneration, cell cycle and stem cells</td></tr><tr><td>&#x02003;NM_000601, NM_001010931, NM_001010932, NM_001010933, NM_001010934</td><td>HGF (Hepatocyte growth factor)</td><td>
<bold>&#x02013;1.20</bold>
</td><td>
<bold>0.0529</bold>
</td><td>&#x02013;<bold>3.40</bold>
</td><td>
<bold>0.0144</bold>
</td><td>&#x02013;1.17</td><td>0.1073</td><td>&#x02013;1.32</td><td>0.5506</td></tr><tr><td>&#x02003;NM_001528.2</td><td>HGFAC (Hepatocyte growth factor activator)</td><td>1.10</td><td>0.4267</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>1.34</bold>
</td><td>
<bold>0.0267</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_001170406, NM_001170407, NM_001786, NM_033379</td><td>CDK1 (cyclin-dependent kinase 1)</td><td>&#x02013;1.20</td><td>0.3340</td><td>&#x02013;1.19</td><td>0.7497</td><td>&#x02013;1.25</td><td>0.2553</td><td>&#x02013;1.31</td><td>0.6225</td></tr><tr><td>&#x02003;NM_031966</td><td>CCNB1 (Cyclin B1)</td><td>&#x02013;1.21</td><td>0.2251</td><td>&#x02013;2.17</td><td>0.2864</td><td>&#x02013;1.38</td><td>0.0558</td><td>&#x02013;2.22</td><td>0.2748</td></tr><tr><td>&#x02003;NM_001255</td><td>CDC20 (cell division cycle 20 homolog)</td><td>&#x02013;1.03</td><td>0.8235</td><td>&#x02013;1.45</td><td>0.5416</td><td>&#x02013;1.18</td><td>0.2489</td><td>&#x02013;1.32</td><td>0.6487</td></tr><tr><td>&#x02003;NM_005556</td><td>CK7 (keratin 7)</td><td>1.08</td><td>0.6855</td><td>&#x02013;2.48</td><td>0.3612</td><td>&#x02013;1.20</td><td>0.3464</td><td>
<bold>&#x02013;12.28</bold>
</td><td>
<bold>0.0178</bold>
</td></tr><tr><td>&#x02003;NM_002276</td><td>CK19 (keratin 19)</td><td>&#x02013;1.16</td><td>0.4008</td><td>&#x02013;2.33</td><td>0.3545</td><td>&#x02013;1.38</td><td>0.0900</td><td>
<bold>&#x02013;13.09</bold>
</td><td>
<bold>0.0092</bold>
</td></tr><tr><td>&#x02003;NM_002838, NM_080921, NM_080923</td><td>PTPRC (CD45) (protein tyrosine phosphatase, receptor type, C)</td><td>
<bold>&#x02013;1.53</bold>
</td><td>
<bold>0.0098</bold>
</td><td>&#x02013;3.61</td><td>0.06</td><td>&#x02013;1.04</td><td>0.8147</td><td>&#x02013;1.32</td><td>0.675</td></tr><tr><td>&#x02003;NM_003122</td><td>SPINK1 (serine peptidase inhibitor, Kazal type 1)</td><td>&#x02013;2.42</td><td>0.0591</td><td>&#x02013;6.19</td><td>0.1449</td><td>&#x02013;1.07</td><td>0.8789</td><td>&#x02013;1.28</td><td>0.8391</td></tr><tr><td>&#x02003;NM_016639</td><td>TNFRSF12A (tumor necrosis factor receptor superfamily, member 12A)</td><td>
<bold>&#x02013;2.02</bold>
</td><td>
<bold>0.0003</bold>
</td><td>
<bold>&#x02013;11.26</bold>
</td><td>
<bold>0.0207</bold>
</td><td>
<bold>&#x02013;1.75</bold>
</td><td>
<bold>0.0016</bold>
</td><td>
<bold>&#x02013;31.33</bold>
</td><td>
<bold>0.0019</bold>
</td></tr><tr><td colspan="10">Fibrosis</td></tr><tr><td>&#x02003;NM_000088</td><td>COL1A1 (collagen, type I, alpha 1)</td><td>
<bold>&#x02013;1.96</bold>
</td><td>
<bold>0.0001</bold>
</td><td>
<bold>&#x02013;5.41</bold>
</td><td>
<bold>0.0181</bold>
</td><td>
<bold>&#x02013;1.47</bold>
</td><td>
<bold>0.0137</bold>
</td><td>&#x02013;1.34</td><td>0.6628</td></tr><tr><td>&#x02003;NM_000089</td><td>COL1A2 (collagen, type I, alpha 2)</td><td>
<bold>&#x02013;2.26</bold>
</td><td>
<bold>0.0001</bold>
</td><td>
<bold>&#x02013;2.17</bold>
</td><td>
<bold>0.0216</bold>
</td><td>
<bold>&#x02013;1.61</bold>
</td><td>
<bold>0.0136</bold>
</td><td>&#x02013;1.53</td><td>0.1871</td></tr><tr><td colspan="10">Metabolism/function</td></tr><tr><td>&#x02003;NM_145740</td><td>GSTA1 (glutathione S-transferase alpha 1)</td><td>
<bold>2.10</bold>
</td><td>
<bold>0.0258</bold>
</td><td>2.51</td><td>0.1955</td><td>
<bold>2.12</bold>
</td><td>
<bold>0.0296</bold>
</td><td>
<bold>7.85</bold>
</td><td>
<bold>0.007</bold>
</td></tr><tr><td>&#x02003;NM_000846</td><td>GSTA2 (glutathione S-transferase alpha 1)</td><td>1.87</td><td>0.0573</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>2.72</bold>
</td><td>
<bold>0.0183</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_000780.3</td><td>CYP7A1 (cytochrome P450, family 7, subfamily A, polypeptide 1)</td><td>
<bold>2.72</bold>
</td><td>
<bold>0.0183</bold>
</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>2.59</bold>
</td><td>
<bold>0.0193</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_000761</td><td>CYP1A2 (cytochrome P450, family 1, subfamily A, polypeptide 2)</td><td>
<bold>2.15</bold>
</td><td>
<bold>0.0073</bold>
</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>2.24</bold>
</td><td>
<bold>0.0067</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_001195728, NM_004171</td><td>SLC1A2 (solute carrier family 1 (glial high affinity glutamate transporter), member 2)</td><td>
<bold>1.38</bold>
</td><td>
<bold>0.064</bold>
</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;1.09</td><td>0.4444</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_005577</td><td>LPA (lipoprotein, Lp(a))</td><td>
<bold>2.18</bold>
</td><td>
<bold>0.0070</bold>
</td><td>
<bold>27.09</bold>
</td><td>
<bold>0.0021</bold>
</td><td>
<bold>2.39</bold>
</td><td>
<bold>0.0041</bold>
</td><td>
<bold>20.77</bold>
</td><td>
<bold>0.0041</bold>
</td></tr><tr><td>&#x02003;NM_000482</td><td>APOA4 (apolipoprotein A-IV)</td><td>
<bold>&#x02013;4.56</bold>
</td><td>
<bold>0.0001</bold>
</td><td>
<bold>&#x02013;17.89</bold>
</td><td>
<bold>0.0053</bold>
</td><td>
<bold>&#x02013;5.97</bold>
</td><td>
<bold>0.0000</bold>
</td><td>
<bold>&#x02013;126.73</bold>
</td><td>0.00001</td></tr><tr><td>&#x02003;NM_020299</td><td>AKR1B10 (aldo-keto reductase family 1, member B10 (aldose reductase))</td><td>
<bold>&#x02013;1.85</bold>
</td><td>
<bold>0.0115</bold>
</td><td>
<bold>&#x02013;1.61</bold>
</td><td>
<bold>0.0302</bold>
</td><td>
<bold>&#x02013;2.23</bold>
</td><td>
<bold>0.0024</bold>
</td><td>
<bold>&#x02013;2.33</bold>
</td><td>
<bold>0.0005</bold>
</td></tr><tr><td>&#x02003;NM_001444, NR_002935</td><td>FABP5/FABP5P3 (fatty acid binding protein 5 (psoriasis-associated)/fatty acid binding protein 5 pseudogene 3)</td><td>
<bold>&#x02013;1.65</bold>
</td><td>
<bold>0.0212</bold>
</td><td>&#x02013;</td><td>&#x02013;</td><td>
<bold>&#x02013;2.07</bold>
</td><td>
<bold>0.0021</bold>
</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x02003;NM_005764</td><td>PDZK1 (PDZK1 interacting protein 1)</td><td>&#x02013;1.49</td><td>0.0972</td><td>&#x02013;5.82</td><td>0.0655</td><td>
<bold>&#x02013;1.73</bold>
</td><td>
<bold>0.0330</bold>
</td><td>
<bold>&#x02013;12.02</bold>
</td><td>
<bold>0.0124</bold>
</td></tr><tr><td>&#x02003;NM_000636, NM_001024465, NM_001024466</td><td>SOD2 (superoxide dismutase 2, mitochondrial)</td><td>
<bold>&#x02013;1.57</bold>
</td><td>
<bold>0.0193</bold>
</td><td>&#x02013;1.21</td><td>0.2164</td><td>
<bold>&#x02013;1.61</bold>
</td><td>
<bold>0.0187</bold>
</td><td>
<bold>&#x02013;1.44</bold>
</td><td>
<bold>0.0267</bold>
</td></tr></tbody></table><table-wrap-foot><p>Values shown in bold are significant at <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec12"><title>Discussion</title><p>Building on our previous report assessing the role of autologous bone marrow stem cell transplantation in AH, we aim to go deeper with this additional analysis in our description of the effect of SCT in AH. Although the invasive strategy that aimed to stimulate regeneration and repair in patients with severe liver failure did not demonstrate clinical benefit over the standard of care treatment, we decided to explore whether specific mechanisms were specifically activated following SCT.</p><p>A moderate, although significant, CD68<sup>+</sup> cell expansion was evident on repeat liver biopsy in patients who received GCSF and SCT as compared to controls. As there is no group with GCSF alone, we are not able to conclude if the increased macrophage content is related to GCSF, to SCT, or to both conditions. This macrophage activation can be interpreted as a negative effect, mainly for two reasons. First, macrophages are part of the innate immune system. Their activation in this situation could be the consequence of the administration of foreign cells originating outside the liver. Indeed, it was speculated by some authors that this macrophage expansion, also evident in rats treated with hepatocyte transplantation, could have a negative impact on the engraftment of the cells [<xref ref-type="bibr" rid="CR17">17</xref>]. Second, infiltration of inflammatory cells and, in particular, macrophages is the hallmark of early and chronic phases of ALD [<xref ref-type="bibr" rid="CR18">18</xref>] and nonalcoholic fatty liver disease (NAFLD) [<xref ref-type="bibr" rid="CR19">19</xref>] where they play a pathogenic role through inflammatory cytokine production and oxidative stress induction. However, CD68<sup>+</sup> cell expansion can also be interpreted as a positive consequence. Indeed, macrophages (through their secretory functions) are also able to stimulate regeneration [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] and to favor LPC transformation into hepatocytes rather than to cholangiocytes [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. In summary, heterogeneity exists in macrophage subsets and functions explaining their ambivalent nature. In asymptomatic early phases of ALD or NAFLD, macrophages play a negative role, taking part in the disease process, whereas in late severe stages with massive hepatocellular death (such as this situation of AH), they are able to promote liver regeneration [<xref ref-type="bibr" rid="CR22">22</xref>]. The identification of one macrophage-derived target mediator (or one specific macrophage population) stimulating liver repair with no or a poor effect on liver injury in AH will be of great interest.</p><p>The data on hepatic gene expression changes induced by a single session of SCT were somewhat disappointing, although anticipated in the view of the negative clinical and biological results. Changes in inflammation and chemotaxis-related genes, in SPINK1, and in CD45 hematopoietic cell/granulocyte markers were evident in SCT patients. However, no change in cell-cycle proteins could be seen, a parameter that has been reported as a positive prognostic indicator in previous studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Nanostring analyses on selected genes revealed a significant upregulation of CD68 (in line with the histological data) and HGF following SCT, and confirmed the upregulation of CD45.</p><p>It is possible that the degree of cell engraftment at the site of injury is low, as we were not able to track the bone marrow-derived cells into the liver. The severe inflammatory condition present in AH could also alter this phenomenon. A reduced potential of regeneration for bone marrow stem cells from patients with cirrhosis was also recently described and correlated with the severity of the liver disease assessed by prognostic factors [<xref ref-type="bibr" rid="CR24">24</xref>]. Another hypothesis is that the bone marrow stimulus in our study (5-day GCSF stimulation followed by one single injection of stem cells in the hepatic artery) was not sufficient to enhance regeneration. In this setting, results of the Realistic study will be of great interest [<xref ref-type="bibr" rid="CR25">25</xref>]. Indeed, this randomized controlled trial will evaluate the impact of GCSF injections with or without repeated (although peripheral) injections of bone marrow stem cells, compared to controls, in compensated cirrhosis.</p></sec><sec id="Sec13"><title>Conclusions</title><p>Our results are consistent with a significant but low impact of SCT on hepatic macrophage expansion and on some macrophage/regenerative/stem cell markers. This macrophage activation in AH, concurrent with higher SPINK1 and HGF mRNA expression in SCT patients, is thus analyzed as a positive factor. However, with the negative results of the clinical trial, it has to be interpreted as a weak impact of stem cell transplantation, which is not able to modify the clinical course of the severe disease. Dysfunction of bone marrow stem cells in severe cirrhosis and the difficulties of engraftment of transplanted cells in a severe target disease in this context of decompensated alcoholic cirrhosis represent two possibilities that might explain the low impact of this SCT strategy. The strengths of this study are the high number of patients included in the histological and transcriptome analysis, as well as the baseline and 4-week liver material, allowing a concordance between the results and the clinical impact of SCT.</p></sec><sec sec-type="supplementary-material"><title>Additional files</title><sec id="Sec14"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13287_2017_541_MOESM1_ESM.pdf"><label>Additional file 1:</label><caption><p>Baseline histological patient characteristics according to treatment allocation. (PDF 105 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="13287_2017_541_MOESM2_ESM.pptx"><label>Additional file 2:</label><caption><p>Liver cell proliferation, macrophage activation, and SPINK1 mRNA expression. This figure shows the expression by immunohistochemistry of K7 (pink), Ki67 (brown) (A) and CD68 (brown) (B), and the mRNA expression of SPINK1 (blue) revealed by in situ hybridization (C). One control patient (CTL) and two different stem cell treated (SCT) patients are illustrated with serial sections at 4&#x000a0;weeks. SPINK1 mRNA positivity could be observed in the liver parenchyma of SCT patients at week 4. (PPTX 2667 kb)</p></caption></media></supplementary-material>
<supplementary-material content-type="local-data" id="MOESM3"><media xlink:href="13287_2017_541_MOESM3_ESM.pptx"><label>Additional file 3:</label><caption><p>Top 3 regulatory gene ontology processes in stem cell treated (SCT) patients identified by MetaCore analysis system at 4&#x000a0;weeks. Using a fold-change threshold of 1.5 and a <italic>p</italic> value lower than 0.05, three sets of biological processes were identified (based on <italic>p</italic> value). A red color next to the gene symbol represents significantly upregulated genes while a green color represents significantly downregulated genes in SCT patients compared to controls. (PPTX 52 kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AH</term><def><p>Alcoholic hepatitis</p></def></def-item><def-item><term>ALD</term><def><p>Alcoholic liver disease</p></def></def-item><def-item><term>COLA1A1</term><def><p>Collagen type 1 alpha1</p></def></def-item><def-item><term>CXCL</term><def><p>C-X-C motif chemokine ligand</p></def></def-item><def-item><term>DR</term><def><p>Ductular reaction</p></def></def-item><def-item><term>GCSF</term><def><p>Granulocyte-colony stimulating factors</p></def></def-item><def-item><term>Hep</term><def><p>Hepatocyte</p></def></def-item><def-item><term>HGF</term><def><p>Hepatocyte growth factor</p></def></def-item><def-item><term>IH</term><def><p>Intermediate hepatocytes</p></def></def-item><def-item><term>iPC</term><def><p>Intermediate liver progenitor cells</p></def></def-item><def-item><term>K7</term><def><p>Keratin 7</p></def></def-item><def-item><term>LPC</term><def><p>Liver progenitor cell</p></def></def-item><def-item><term>MELD</term><def><p>Model for end-stage liver disease</p></def></def-item><def-item><term>NAFLD</term><def><p>Nonalcoholic fatty liver disease</p></def></def-item><def-item><term>SCT</term><def><p>Stem cell therapy</p></def></def-item><def-item><term>SPINK1</term><def><p>Serine peptidase inhibitor Kazal type 1</p></def></def-item><def-item><term>TNFRSF12A</term><def><p>Tumor necrosis factor receptor superfamily member 12A</p></def></def-item><def-item><term>TWEAK</term><def><p>Tumor necrosis factor-like weak inducer of apoptosis</p></def></def-item></def-list></glossary><ack><title>Acknowledgements</title><p>The authors are very grateful to the iGE3 Genomics Platform of the University of Geneva for the transcriptome and subsequent statistical analyses, as well as for the discussions during the study.</p><sec id="FPar1"><title>Funding</title><p>This study was funded by the Clinical Research Center, University Hospital and Faculty of Medicine, Geneva, the Louis-Jeantet Foundation and FLAGS (Foundation for Liver and Gut Studies) in Geneva. Finally, the authors also thank the Fondation Saint-Luc (Brussels) for the research and travel bursary for NL.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The gene expression datasets generated and analyzed during the current study are available in ArrayExpress (<ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/arrayexpress/">https://www.ebi.ac.uk/arrayexpress/</ext-link>) accession no. E-MTAB-2664.</p></sec><sec id="FPar3"><title>Authors&#x02019; contributions</title><p>NL: acquisition, analysis and interpretation of data, and drafting of the manuscript; NLM: acquisition, analysis and interpretation of data, and critical revision of the manuscript; LRB: analysis and interpretation of data, and critical revision of the manuscript; SC: acquisition of data, analysis and interpretation of data, and critical revision of the manuscript; NG: critical revision of the manuscript for important intellectual content; LS: study concept and design, acquisition and interpretation of data, drafting of the manuscript, obtained funding, and study supervision. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable. Our manuscript does not contain any individual personal data.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>Written informed consent was obtained in all cases and the study was accepted by our institution ethics committee. The study protocol was in accordance with International Committee for Harmonization/Good Clinical Practice (ICH/GCP) and approved both by our institution Ethics Committee (# 07-145) and the Swiss regulatory authorities (# 2008DR2031).</p></sec><sec id="FPar7"><title>Publisher&#x02019;s Note</title><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathurin</surname><given-names>P</given-names></name></person-group><article-title>Therapeutic management of alcoholic hepatitis</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2015</year><volume>39</volume><issue>Suppl 1</issue><fpage>S41</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.clinre.2015.05.015</pub-id><pub-id pub-id-type="pmid">26189979</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garg</surname><given-names>V</given-names></name><name><surname>Garg</surname><given-names>H</given-names></name><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Trehanpati</surname><given-names>N</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Granulocyte colony-stimulating factor mobilizes CD34(+) cells and improves survival of patients with acute-on-chronic liver failure</article-title><source>Gastroenterology</source><year>2012</year><volume>142</volume><fpage>505</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2011.11.027</pub-id><pub-id pub-id-type="pmid">22119930</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>AK</given-names></name><name><surname>Narasimhan</surname><given-names>RL</given-names></name><name><surname>Bhalla</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><name><surname>Sharma</surname><given-names>R</given-names></name></person-group><article-title>Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study</article-title><source>Am J Gastroenterol</source><year>2014</year><volume>109</volume><fpage>1417</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1038/ajg.2014.154</pub-id><pub-id pub-id-type="pmid">24935272</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lyra</surname><given-names>AC</given-names></name><name><surname>Soares</surname><given-names>MB</given-names></name><name><surname>da Silva</surname><given-names>LF</given-names></name><name><surname>Braga</surname><given-names>EL</given-names></name><name><surname>Oliveira</surname><given-names>SA</given-names></name><name><surname>Fortes</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short-term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study</article-title><source>Eur J Gastroenterol Hepatol</source><year>2010</year><volume>22</volume><fpage>33</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1097/MEG.0b013e32832eb69a</pub-id><pub-id pub-id-type="pmid">19654548</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salama</surname><given-names>H</given-names></name><name><surname>Zekri</surname><given-names>AR</given-names></name><name><surname>Bahnassy</surname><given-names>AA</given-names></name><name><surname>Medhat</surname><given-names>E</given-names></name><name><surname>Halim</surname><given-names>HA</given-names></name><name><surname>Ahmed</surname><given-names>OS</given-names></name><etal/></person-group><article-title>Autologous CD34+ and CD133+ stem cells transplantation in patients with end stage liver disease</article-title><source>World J Gastroenterol</source><year>2010</year><volume>16</volume><fpage>5297</fpage><lpage>305</lpage><pub-id pub-id-type="doi">10.3748/wjg.v16.i42.5297</pub-id><pub-id pub-id-type="pmid">21072892</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>JK</given-names></name><name><surname>Stutchfield</surname><given-names>BM</given-names></name><name><surname>Forbes</surname><given-names>SJ</given-names></name></person-group><article-title>Systematic review: the effects of autologous stem cell therapy for patients with liver disease</article-title><source>Aliment Pharmacol Ther</source><year>2014</year><volume>39</volume><fpage>673</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1111/apt.12645</pub-id><pub-id pub-id-type="pmid">24528093</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanthier</surname><given-names>N</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Spahr</surname><given-names>L</given-names></name></person-group><article-title>Liver progenitor cells and therapeutic potential of stem cells in human chronic liver diseases</article-title><source>Acta Gastroenterol Belg</source><year>2013</year><volume>76</volume><fpage>3</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23650775</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spahr</surname><given-names>L</given-names></name><name><surname>Chalandon</surname><given-names>Y</given-names></name><name><surname>Terraz</surname><given-names>S</given-names></name><name><surname>Kindler</surname><given-names>V</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Frossard</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Autologous bone marrow mononuclear cell transplantation in patients with decompensated alcoholic liver disease: a randomized controlled trial</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e53719</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0053719</pub-id><pub-id pub-id-type="pmid">23341981</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elsegood</surname><given-names>CL</given-names></name><name><surname>Chan</surname><given-names>CW</given-names></name><name><surname>Degli-Esposti</surname><given-names>MA</given-names></name><name><surname>Wikstrom</surname><given-names>ME</given-names></name><name><surname>Domenichini</surname><given-names>A</given-names></name><name><surname>Lazarus</surname><given-names>K</given-names></name><etal/></person-group><article-title>Kupffer cell-monocyte communication is essential for initiating murine liver progenitor cell-mediated liver regeneration</article-title><source>Hepatology</source><year>2015</year><volume>62</volume><fpage>1272</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1002/hep.27977</pub-id><pub-id pub-id-type="pmid">26173184</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanthier</surname><given-names>N</given-names></name><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Lin-Marq</surname><given-names>N</given-names></name><name><surname>Clement</surname><given-names>S</given-names></name><name><surname>Frossard</surname><given-names>JL</given-names></name><name><surname>Goossens</surname><given-names>N</given-names></name><etal/></person-group><article-title>Hepatic cell proliferation plays a pivotal role in the prognosis of alcoholic hepatitis</article-title><source>J Hepatol</source><year>2015</year><volume>63</volume><fpage>609</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2015.04.003</pub-id><pub-id pub-id-type="pmid">25872168</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viebahn</surname><given-names>CS</given-names></name><name><surname>Benseler</surname><given-names>V</given-names></name><name><surname>Holz</surname><given-names>LE</given-names></name><name><surname>Elsegood</surname><given-names>CL</given-names></name><name><surname>Vo</surname><given-names>M</given-names></name><name><surname>Bertolino</surname><given-names>P</given-names></name><etal/></person-group><article-title>Invading macrophages play a major role in the liver progenitor cell response to chronic liver injury</article-title><source>J Hepatol</source><year>2010</year><volume>53</volume><fpage>500</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2010.04.010</pub-id><pub-id pub-id-type="pmid">20561705</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>EASL guidelines</collab></person-group><article-title>EASL clinical practical guidelines: management of alcoholic liver disease</article-title><source>J Hepatol</source><year>2012</year><volume>57</volume><fpage>399</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2012.04.004</pub-id><pub-id pub-id-type="pmid">22633836</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gilchrist</surname><given-names>ES</given-names></name><name><surname>Plevris</surname><given-names>JN</given-names></name></person-group><article-title>Bone marrow-derived stem cells in liver repair: 10&#x000a0;years down the line</article-title><source>Liver Transpl</source><year>2010</year><volume>16</volume><fpage>118</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1002/lt.21965</pub-id><pub-id pub-id-type="pmid">20104479</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Farrell</surname><given-names>GC</given-names></name><name><surname>Fung</surname><given-names>C</given-names></name><name><surname>George</surname><given-names>J</given-names></name></person-group><article-title>Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response</article-title><source>Hepatology</source><year>2002</year><volume>36</volume><fpage>1266</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1053/jhep.2002.36370</pub-id><pub-id pub-id-type="pmid">12395339</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolstad</surname><given-names>BM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Astrand</surname><given-names>M</given-names></name><name><surname>Speed</surname><given-names>TP</given-names></name></person-group><article-title>A comparison of normalization methods for high density oligonucleotide array data based on variance and bias</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><fpage>185</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/19.2.185</pub-id><pub-id pub-id-type="pmid">12538238</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanthier</surname><given-names>N</given-names></name><name><surname>Spahr</surname><given-names>L</given-names></name></person-group><article-title>SPINK1, hepatic macrophages and progenitor cells: new tools for liver regeneration in alcoholic hepatitis?</article-title><source>Med Sci (Paris)</source><year>2016</year><volume>32</volume><fpage>149</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1051/medsci/20163202005</pub-id><pub-id pub-id-type="pmid">26936169</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krohn</surname><given-names>N</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><name><surname>Enami</surname><given-names>Y</given-names></name><name><surname>Follenzi</surname><given-names>A</given-names></name><name><surname>Bandi</surname><given-names>S</given-names></name><name><surname>Joseph</surname><given-names>B</given-names></name><etal/></person-group><article-title>Hepatocyte transplantation-induced liver inflammation is driven by cytokines-chemokines associated with neutrophils and Kupffer cells</article-title><source>Gastroenterology</source><year>2009</year><volume>136</volume><fpage>1806</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2009.01.063</pub-id><pub-id pub-id-type="pmid">19422086</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>Y</given-names></name><name><surname>Bradford</surname><given-names>BU</given-names></name><name><surname>Gao</surname><given-names>W</given-names></name><name><surname>Bojes</surname><given-names>HK</given-names></name><name><surname>Thurman</surname><given-names>RG</given-names></name></person-group><article-title>Inactivation of Kupffer cells prevents early alcohol-induced liver injury</article-title><source>Hepatology</source><year>1994</year><volume>20</volume><fpage>453</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1002/hep.1840200227</pub-id><pub-id pub-id-type="pmid">8045507</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lanthier</surname><given-names>N</given-names></name></person-group><article-title>Targeting Kupffer cells in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: why and how?</article-title><source>World J Hepatol</source><year>2015</year><volume>7</volume><fpage>2184</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.4254/wjh.v7.i19.2184</pub-id><pub-id pub-id-type="pmid">26380042</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boulter</surname><given-names>L</given-names></name><name><surname>Govaere</surname><given-names>O</given-names></name><name><surname>Bird</surname><given-names>TG</given-names></name><name><surname>Radulescu</surname><given-names>S</given-names></name><name><surname>Ramachandran</surname><given-names>P</given-names></name><name><surname>Pellicoro</surname><given-names>A</given-names></name><etal/></person-group><article-title>Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease</article-title><source>Nat Med</source><year>2012</year><volume>18</volume><fpage>572</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/nm.2667</pub-id><pub-id pub-id-type="pmid">22388089</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Hul</surname><given-names>N</given-names></name><name><surname>Lanthier</surname><given-names>N</given-names></name><name><surname>Espanol Suner</surname><given-names>R</given-names></name><name><surname>Abarca Quinones</surname><given-names>J</given-names></name><name><surname>Van Rooijen</surname><given-names>N</given-names></name><name><surname>Leclercq</surname><given-names>I</given-names></name></person-group><article-title>Kupffer cells influence parenchymal invasion and phenotypic orientation, but not the proliferation, of liver progenitor cells in a murine model of liver injury</article-title><source>Am J Pathol</source><year>2011</year><volume>179</volume><fpage>1839</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2011.06.042</pub-id><pub-id pub-id-type="pmid">21854752</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>B</given-names></name><name><surname>Tsukamoto</surname><given-names>H</given-names></name></person-group><article-title>Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe?</article-title><source>Gastroenterology</source><year>2016</year><volume>150</volume><fpage>1704</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2016.01.025</pub-id><pub-id pub-id-type="pmid">26826669</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>JW</given-names></name><name><surname>Bird</surname><given-names>GL</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Davis</surname><given-names>GL</given-names></name><name><surname>Lau</surname><given-names>JY</given-names></name></person-group><article-title>Hepatocyte proliferation as an indicator of outcome in acute alcoholic hepatitis</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>820</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(94)92025-7</pub-id><pub-id pub-id-type="pmid">7908077</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bihari</surname><given-names>C</given-names></name><name><surname>Anand</surname><given-names>L</given-names></name><name><surname>Rooge</surname><given-names>S</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Saxena</surname><given-names>P</given-names></name><name><surname>Shubham</surname><given-names>S</given-names></name><etal/></person-group><article-title>Bone marrow stem cells and their niche components are adversely affected in advanced cirrhosis of the liver</article-title><source>Hepatology</source><year>2016</year><volume>64</volume><fpage>1273</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1002/hep.28754</pub-id><pub-id pub-id-type="pmid">27486864</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>A</given-names></name><name><surname>Barton</surname><given-names>D</given-names></name><name><surname>Beard</surname><given-names>HA</given-names></name><name><surname>Than</surname><given-names>N</given-names></name><name><surname>Moore</surname><given-names>J</given-names></name><name><surname>Corbett</surname><given-names>C</given-names></name><etal/></person-group><article-title>REpeated AutoLogous Infusions of STem cells In Cirrhosis (REALISTIC): a multicentre, phase II, open-label, randomised controlled trial of repeated autologous infusions of granulocyte colony-stimulating factor (GCSF) mobilised CD133+ bone marrow stem cells in patients with cirrhosis. A study protocol for a randomised controlled trial</article-title><source>BMJ Open</source><year>2015</year><volume>5</volume><fpage>e007700</fpage><pub-id pub-id-type="doi">10.1136/bmjopen-2015-007700</pub-id><pub-id pub-id-type="pmid">25795699</pub-id></element-citation></ref></ref-list></back></article>